Results 141 to 150 of about 85,259 (288)

Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Alzheimer’s disease (AD) is a neurodegenerative condition that causes cognitive decline, memory loss, and reduced personal autonomy. The pathology of AD involves the aggregation of abnormal brain proteins, specifically beta-amyloid plaques and tau ...
Taha Basit Ameen, Syeda Naveera Kashif, Syed Muhammad Iraj Abbas, Kulsoom Babar, Syed Muhammad Sinaan Ali, Abdul Raheem   +5 more
doaj   +1 more source

GLIS2 Promotes Epithelial‐Mesenchymal Transition and Gastric Cancer Progression by Regulating BGN to Activate the Wnt/β‐Catenin Pathway

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study elucidates the mechanism by which GLIS Family Zinc Finger 2 (GLIS2) promotes epithelial‐mesenchymal transition (EMT) in gastric cancer through biglycan (BGN) activation and Wnt/β‐catenin stimulation. By analyzing 18 pairs of GC tissues and establishing in vitro models (combining GLIS2 knockdown/BGN overexpression with Wnt pathway ...
Juan Yan, Ya‐Peng Deng
wiley   +1 more source

Evaluation of HER2 Targeted Poly(Ethylene Glycol)‐Poly(L‐histidine) Copolymer Micelles in Breast Cancer Models

Macromolecular Bioscience, EarlyView.
This study reports on the in vitro, ex vivo, and in vivo evaluation of HER2 targeted biodegradable micelle variants, conjugated with trastuzumab, with or without the drug doxorubicin or the dye rhodamine B. Findings indicate enhanced cellular association and efficacy of trastuzumab‐conjugated micelles in HER2 positive breast cancer models, showing ...
Remya Valsala Kumari, Abhilash D. Pandya, Solveig J. Pettersen, Audun Kvalvaag, Anne Grethe Myrann, Razvan Ghiarasim, Alexandru Rotaru, Mihail‐Gabriel Dimofte, Tore Skotland, Kirsten Sandvig, Gunhild Mari Mælandsmo, Tore‐Geir Iversen   +11 more
wiley   +1 more source

Intratumoral Nerve Phased Development: A Promising Therapeutic Target

Medicine Bulletin, EarlyView.
ABSTRACT The nervous system has emerged as a critical regulator of tumor biology, engaging in dynamic crosstalk with cancer cells. Although the protumorigenic role of innervation is well established, increasing attention is now directed toward reciprocal influences—how tumors actively shape and remodel local nerve networks within the tumor ...
Xiangxian Che, Hang Wang, Han Wang, Yi‐Zhou Jiang   +3 more
wiley   +1 more source

Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Combining immune checkpoint inhibitors (ICI) with chemotherapy may improve treatment response in children with solid tumors. We sought to determine the feasibility of combining vincristine, irinotecan, and temozolomide with the ICI atezolizumab in children with relapsed or refractory solid tumors (VITAS;). Methods Patients ≥6 months
Matthew E. Campbell, Sonja Stutzman, Sharon Primeaux, Deseray Sida, Minjae Lee, Avanthi T. Shah, Arhanti Sadanand, Elizabeth Sokol, Natalie B. Collins, Brian Turpin, Shoba Navai, Katie Albert, Theodore W. Laetsch, Dinesh Rakheja, Kenneth S. Chen, David E. Gerber, Andrew Y. Koh   +16 more
wiley   +1 more source

Hemophilia A: An Ideal Disease for Prenatal Therapy

Prenatal Diagnosis, EarlyView.
ABSTRACT Hemophilia A (HA) is the most common inherited coagulation defect. Current state‐of‐the‐art treatment consists of frequent administration of prophylactic infusions of coagulation factor VIII (FVIII) protein or bispecific antibodies that replace the cofactor function of FVIIIa to maintain hemostasis. However, these treatments are far from ideal,
Christopher D. Porada, Anthony Atala, Graça Almeida‐Porada   +2 more
wiley   +1 more source

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani, Laiyi Chua, Wendy J. Komocsar, Amy Larkin, Jordan Johns, Xin Zhang   +5 more
wiley   +1 more source

Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Evinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). Herein, we report pharmacokinetic and efficacy analyses of evinacumab in < 5‐year‐old patients with HoFH.
Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Katy C. Norman, Richard T. George, Xue‐Qiao Zhao, Robert Pordy, Daniel Garcia, Wendy S. Putnam, Geetha Raghuveer, Brian W. McCrindle, Elena Fornari, Ivo Baric, Shubha Srinivasan, Melissa Diamond, Eliot A. Brinton, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch   +18 more
wiley   +1 more source

Mitigating Trastuzumab‐Doxorubicin Cardiotoxicity With Multiscale Quantitative Systems Toxicology and PBPK‐Toxicodynamic Predictive Modeling Framework

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Doxorubicin (DOX) and trastuzumab (TmAb) are widely used to treat HER2‐positive breast cancer (BC), as monotherapies and in combination (DOX + TmAb). While highly effective, their combined use significantly increases the risk of irreversible cardiotoxicity, posing a major clinical concern.
Sijia Yu, Hardik Mody, Tanaya R. Vaidya, Leonid Kagan, Sihem Ait‐Oudhia   +4 more
wiley   +1 more source

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

Pharmacogenomics and Personalized Medicine, 2014
Lukáš Smolej 4th Department of Internal Medicine – Hematology, University Hospital Hradec Králové and Charles University in Prague, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech
Smolej L
doaj